• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Systematic review evaluating cardiovascular events of the 5‐alpha reductase inhibitor – Dutasteride
Summary What is known and objectivesA recently published large, long‐term randomized controlled trial (RCT) brought into question the safety of dutasteride after a significantly increased risk of ‘cardiac failure’ was noted in the dutasteride arm of the trial compared with placebo. Our objective was to perform a meta‐analysis to assess the risk of cardiovascular adverse events with the use of dutasteride for the prevention or treatment of prostatic disease. MethodsWe searched MEDLINE and EMBASE, unpublished articles identified through FDA/EMEA websites, study registers of pharmaceutical companies and reference list...
Source: Journal of Clinical Pharmacy and Therapeutics - July 1, 2013 Category: Drugs & Pharmacology Authors: Y. K. Loke, R. Ho, M. Smith, O. Wong, M. Sandhu, W. Sage, S. Singh Tags: Original Article Source Type: research